Seminars in Nuclear Medicine

Papers
(The TQCC of Seminars in Nuclear Medicine is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Theranostics in Lung Neuroendocrine Tumors111
Letter from the Guest Editors106
Non-FDG hypoxia tracers91
Letter from the Editors61
Neurological Disorders and Women's Health: Contribution of Molecular Neuroimaging Techniques58
Highlighting New Research Trends on Zirconium-89 Radiopharmaceuticals Beyond Antibodies54
Sentinel Lymph Node Methods in Breast Cancer49
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update47
Imaging of Invasive Fungal Infections- The Role of PET/CT41
FAPI-PET in Cardiovascular Disease40
Controversies in the Radioiodine Treatment of Patients With Differentiated Thyroid Cancer38
Autoimmune Thyroid Diseases38
Molecular Imaging in Inflammatory Bowel Disease38
Artificial Intelligence for Drug Discovery: An Update and Future Prospects37
The Role of Nuclear Medicine in Benign Thyroid Disease36
Pediatric Nephro-Urology: Overview and Updates in Diuretic Renal Scans and Renal Cortical Scintigraphy35
Imaging for Radiation Planning in Breast Cancer34
Selective Internal Radiotherapy in Liver Tumors: Early Promise Yet to be Fulfilled33
Prognostic Value of PSMA PET/CT in Prostate Cancer32
Global experience in brain amyloid imaging31
Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers31
Radionuclide Imaging of Cardiac Amyloidosis: An Update and Future Aspects30
The Evolution of Artificial Intelligence in Nuclear Medicine30
Total-Body PET/CT: A Role of Artificial Intelligence?30
FDG PET/CT for Detection of Infectious Complications Following Solid Organ Transplantation28
Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity28
Current and Future Perspective of PET/CT in Response Assessment of Malignant Pleural Mesothelioma27
PET/MR Technology: Advancement and Challenges27
Remote Reading and Teaching of Nuclear Medicine in the Era of COVID-1927
Imaging of Cardiac Sarcoidosis: An Update and Future Aspects26
The Role of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) in the Diagnosis and Evaluation of Spondylodiscitis25
Artificial intelligence for tumor [18F]FDG-PET imaging: Advancement and future trends—part I24
Expanding Role for Gallium-68 PET Imaging in Oncology24
Standardized PSMA-PET Imaging of Advanced Prostate Cancer23
Use of Radionuclide-Based Imaging Methods in Breast Cancer23
New Approaches for Imaging Bacteria23
Letter from the Guest Editors22
Total-body PET/CT – First Clinical Experiences and Future Perspectives21
Letter From the Editors21
Scintigraphic Diagnosis of Acute Pulmonary Embolism: From Basics to Best Practices21
Total Body Positron Emission Tomography/Computed Tomography: Current Status in Oncology20
18F-Fluoride PET/CT—Updates20
Update on Pediatric Nuclear Medicine in Acute Care19
FDG PET/CT for Staging Lung Carcinoma: An Update19
Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine19
Impact of COVID-19 on Nuclear Medicine in Asia19
Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?18
Letter from the Editors18
18F-Sodium Fluoride PET/CT in Assessing Valvular Heart and Atherosclerotic Diseases18
Practice of 18F-FDG-PET/CT in ICU Patients: A Systematic Review18
Nuclear Medicine Preclinical Research: The Role of Cell Cultures17
Targeted Radiopharmaceutical Therapy for Bone Metastases16
Diagnosis and Image-guided Therapy of Cardiac Left Ventricular Assist Device Infections16
Safe Pulmonary Scintigraphy in the Era of COVID-1916
Functional Imaging of Testicular Torsion16
Radiolabeled Somatostatin Analogs for Cancer Imaging16
The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment16
The Clinical Utility of Molecular Imaging in COVID-19: An Update16
Advances in PET Imaging of Large Vessel Vasculitis: An Update and Future Trends15
Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma15
Academic integrity and artificial intelligence: is ChatGPT hype, hero or heresy?15
Optimizing CT Imaging Parameters: Implications for Diagnostic Accuracy in Nuclear Medicine15
The Impact of COVID-19 on Nuclear Medicine in Europe15
Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET14
Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers Part II. [F]F-FLT, [F]F-FET, [C]C-MET and Other Less-Commonly Used Radiotrace14
Artificial Intelligence and Workforce Diversity in Nuclear Medicine14
PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget14
Letter from the Editors14
FDG-PET/CT Variants and Pitfalls in Haematological Malignancies14
How to Perform FAPI PET? An Expedited Systematic Review Providing a Recommendation for FAPI PET Imaging With Different FAPI Tracers13
PET/CT Variants and Pitfalls in Gynecological Cancers13
Prostate Cancer Theranostics With 177Lu-PSMA13
Radiomics and Artificial Intelligence Landscape for [18F]FDG PET/CT in Multiple Myeloma13
Telehealth in Multidisciplinary Target Delineation for Radiotherapy During the COVID-19 Pandemic. A Review and a Case13
Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides13
FDG-PET/CT of COVID-19 and Other Lung Infections13
A Role of Non-FDG Tracers in Lung Cancer?13
Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy13
Hybrid Imaging: Calcium Score and Myocardial Perfusion Imaging12
PET Assessment of Cardiac Allograft Vasculopathy12
A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging12
Letter From the Guest Editors12
COVID-19 Pandemic: What Have We Learned and What to Expect in the Future?12
Imaging in Renal Transplants: An Update12
Letter From the Editors12
Radiation Dose to Pediatric Patients From Radiopharmaceuticals12
0.28703689575195